These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6850667)

  • 61. VP16-213 (etoposide). A critical review of its activity.
    Cavalli F
    Cancer Chemother Pharmacol; 1982; 7(2-3):81-5. PubMed ID: 7044594
    [No Abstract]   [Full Text] [Related]  

  • 62. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 63. Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma.
    Hartmann JT; Kanz L; Bokemeyer C
    Anticancer Res; 2000; 20(2B):1177-82. PubMed ID: 10810418
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Results of the treatment of lymphatic neoplasms with Vepeside].
    Pawlicki M; Sliz E
    Nowotwory; 1985; 35(2):145-50. PubMed ID: 3911173
    [No Abstract]   [Full Text] [Related]  

  • 65. Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer.
    Perez Manga G; Madrigal Alonso PL; Alburquerque Carbuccia H
    Cancer Chemother Pharmacol; 1982; 7(2-3):227-9. PubMed ID: 6805972
    [No Abstract]   [Full Text] [Related]  

  • 66. Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E; Zipoli T; Gonzalves L
    J Infus Chemother; 1996; 6(1):43-6. PubMed ID: 8748007
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 68. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
    Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Teniposide in refractory ovarian cancer: a phase II study.
    Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
    Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
    [No Abstract]   [Full Text] [Related]  

  • 70. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.
    Scher HI; Sternberg C; Heston WD; Watson RC; Niedzwiecki D; Smart T; Hollander P; Yagoda A
    Cancer Chemother Pharmacol; 1986; 18(1):24-6. PubMed ID: 3757155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
    Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
    Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience.
    Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
    Cancer Treat Rep; 1986 Nov; 70(11):1337-8. PubMed ID: 3768877
    [No Abstract]   [Full Text] [Related]  

  • 74. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
    Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
    Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Etoposide for therapy-resistant testicular tumors.
    Varini M; Cavalli F
    Cancer Treat Rev; 1982 Jun; 9 Suppl():73-8. PubMed ID: 7127337
    [No Abstract]   [Full Text] [Related]  

  • 76. The activity of paclitaxel in gastrointestinal tumors.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
    Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy.
    Caruso R; Alesiani F; Latagliata R
    Haematologica; 1997; 82(1):126-7. PubMed ID: 9107103
    [No Abstract]   [Full Text] [Related]  

  • 79. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Lewandowski GS; Creasman WT; Webster KD
    Gynecol Oncol; 1996 Oct; 63(1):101-4. PubMed ID: 8898177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.